div class=ts-pagebuttonPage 1button div class=ts-image amp-img class=ts-thumb alt=Page 1: Erbitux仿單 - ndmctsghedutwErbitux in combination with irinotecan is indicated for the treatment of patients with epiderma growth factor receptor EGFR-expressing metastatic co src=https:reader034vdocumentinreader034viewer20220421075e865064c3229a074e01d743html5thumbnails1jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 2button div class=ts-image amp-img class=ts-thumb alt=Page 2: Erbitux仿單 - ndmctsghedutwErbitux in combination with irinotecan is indicated for the treatment of patients with epiderma growth factor receptor EGFR-expressing metastatic co src=https:reader034vdocumentinreader034viewer20220421075e865064c3229a074e01d743html5thumbnails2jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 3button div class=ts-image amp-img class=ts-thumb alt=Page 3: Erbitux仿單 - ndmctsghedutwErbitux in combination with irinotecan is indicated for the treatment of patients with epiderma growth factor receptor EGFR-expressing metastatic co src=https:reader034vdocumentinreader034viewer20220421075e865064c3229a074e01d743html5thumbnails3jpg width=142 height=106 layout=responsive amp-img divdiv